TORL-2-307-ADC / TORL Biotherap - LARVOL DELTA

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer (clinicaltrials.gov) - P1 | N=163 | Active, not recruiting | Sponsor: TORL Biotherapeutics, LLC | Recruiting ➔ Active, not recruiting | N=70 ➔ 163 | Trial primary completion date: Feb 2026 ➔ Jun 2026

Enrollment change • Enrollment closed • First-in-human • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Pancreatic Cancer • Solid Tumor

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: TORL Biotherapeutics, LLC | Trial completion date: Jan 2026 ➔ Feb 2027 | Trial primary completion date: Jan 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline (PRNewswire) - "Proceeds from this Series B-2 financing will be used to continue the clinical development of TORL-1-23, the Company's first-in-class ADC to treat CLDN 6+ tumors, through Phase 1 and a pivotal Phase 2 trial that will start in the second half of 2024....Proceeds will also be used to fund the on-going Phase 1 studies for the TORL-2-307 program, both a monoclonal antibody (mAb) and an ADC, for the treatment of CLDN 18.2+ solid tumors, TORL-3-600, an ADC for the treatment of CDH17+ colorectal cancer, and TORL-4-500, an ADC for the treatment of Delta like non-canonical Notch Ligand 1 (DLK1) positive solid tumors."

Financing • New P1 trial • New P2 trial • Colorectal Cancer • Gastroesophageal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

First in Human Study of TORL-3-600 in Participants With Advanced Cancer (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: TORL Biotherapeutics, LLC

New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics (PRNewswire) - "TORL BioTherapeutics LLC...announced today its public launch and the closing of a $158 million Series B financing....The Company also expects to put 2-3 additional compounds into clinical trials over the next 12 months, with plans to advance 1-2 new compounds each year....'We believe TORL-1-23 and TORL-2-307 represent promising potential therapies for ovarian and gastric cancers, two indications with significant unmet patient need. We look forward to partnering with the TORL team to rapidly advance the lead programs toward late-stage clinical trials while progressing the broader portfolio of novel programs."

Financing • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Ministry of Food and Drug Safety approves 5 clinical trials including Chong Kun Dang hair loss treatment drug [Google translation] - "Roche Korea has been approved for a phase 2 clinical trial of the bispecific antibody 'RO7247669'. To compare and evaluate 'RO7247669' and platinum-based chemotherapy versus 'pembrolizumab' and platinum-based chemotherapy in 19 Korean patients with locally advanced or metastatic non-small cell lung cancer who had no previous treatment experience...The Korean Cancer Therapy Research Association has been approved for a phase 1 study of 'TORL-2-307-ADC, a treatment for advanced solid cancer....U.S. Panbela Therapeutics received approval for the Phase 2/3 clinical trial of 'SBP-101' through the clinical trial consignment agency, PPD Development, PT ELT. To evaluate the efficacy of nap paclitaxel and gemcitabine with or without 'SBP-101' in 12 domestic patients who have not previously received treatment for metastatic pancreatic ductal adenocarcinoma."

New P1 trial • New P2 trial • New P2/3 trial • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

"TORL-2-307-ADChttps://www.adcreview.com/drugmap/torl-2-307-adc/" (@OncoZine)

Review

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: TORL Biotherapeutics, LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor